Yeldandi A V, Milano M, Subbarao V, Reddy J K, Rao M S
Department of Pathology, Northwestern University Medical School, Chicago, IL 60611.
Cancer Lett. 1989 Sep 15;47(1-2):21-7. doi: 10.1016/0304-3835(89)90172-9.
To determine if the carcinogenic potential of peroxisome proliferators is dependent upon their ability to induce cell proliferation, we have investigated the extent of cell proliferation in the livers of rats fed ciprofibrate, a peroxisome proliferator. Male rats were maintained on a diet containing ciprofibrate (0.025% w/w) and killed at selected intervals following 1 week of continuous [3H]thymidine labeling. Evaluation of labeling indices demonstrated a significant increase in cell proliferation during the first week but not in rats killed at the end of 5 and 20 weeks of treatment. Increases in hepatocyte nuclear labeling were found at 40 and 70 weeks of ciprofibrate administration which coincided with the appearance in livers of putative preneoplastic and neoplastic lesions. In a short-term feeding study, ciprofibrate and ethoxyquin were fed to rats at a dietary concentration of 0.025% and 0.5%, respectively, either alone or in combination for 7 days. Ciprofibrate and ethoxyquin either alone or in combination produced marked hepatomegaly and a significant increase in DNA synthesis as demonstrated by [3H]thymidine incorporation and autoradiographic studies. DNA synthesis in the group receiving ciprofibrate and ethoxyquin simultaneously, was slightly more than in animals that received either compound alone, suggesting a synergistic effect, although chronic feeding of these agents together resulted in inhibition of liver carcinogenesis (Rao, M. S. et al. (1984) Cancer Res., 44, 1072-1076). The results of this study further suggest that cell proliferation induced by peroxisome proliferators may be less important in carcinogenesis than peroxisome proliferation induced by these compounds.
为了确定过氧化物酶体增殖剂的致癌潜力是否取决于它们诱导细胞增殖的能力,我们研究了喂食环丙贝特(一种过氧化物酶体增殖剂)的大鼠肝脏中的细胞增殖程度。雄性大鼠维持在含环丙贝特(0.025% w/w)的饮食中,并在连续[3H]胸腺嘧啶核苷标记1周后的选定时间点处死。标记指数评估显示,在治疗的第一周细胞增殖显著增加,但在治疗5周和20周结束时处死的大鼠中未增加。在环丙贝特给药40周和70周时发现肝细胞核标记增加,这与肝脏中假定的癌前病变和肿瘤性病变的出现一致。在一项短期喂养研究中,分别以0.025%和0.5%的饮食浓度将环丙贝特和乙氧喹单独或联合喂给大鼠7天。单独或联合使用环丙贝特和乙氧喹均导致明显的肝肿大以及[3H]胸腺嘧啶核苷掺入和放射自显影研究所示的DNA合成显著增加。同时接受环丙贝特和乙氧喹的组中的DNA合成略高于单独接受任何一种化合物的动物,表明存在协同作用,尽管长期同时喂食这些药物会抑制肝癌发生(Rao, M. S.等人(1984年),《癌症研究》,44,1072 - 1076)。这项研究的结果进一步表明,过氧化物酶体增殖剂诱导的细胞增殖在致癌过程中可能不如这些化合物诱导的过氧化物酶体增殖重要。